PRESS RELEASE. The Swedish diagnostics company SAGA Diagnostics, which develops ultrasensitive liquid biopsy tests for early detection of cancer relapse…Read more
NEW COMPANY AT SCIETY. Osteoarthritis affects more than 320 million people globally and is a leading source of chronic pain…Read more
The investment syndicate
Join the Sciety investment syndicate and receive personal invitations to company presentation events and be the first to get exclusive information about selected companies. Sciety membership is free and a minimum investment is SEK 100,000.
Services we offer
Sciety offers capital market services with a focus on Swedish life science. Based on extensive industry experience, we offer services to investors, growth companies and industrial players within life science.
What our clients say
“We are very pleased with the outcome of the financing round through Sciety. The whole process was efficient and went very smoothly thanks to Sciety's competent and professional team. It was a fun and constructive collaboration.”
Malte Kühnemund, CEO Cartana
From late preclinical trial phase to Phase II clinical trials. All therapeutic areas.
From clinical validation phase to expansion phase.
From late preclinical phase to Phase II clinical trials. All therapeutic areas.
From clinical validation to expansion phase. All indications.
ICT in healthcare
From pilot phase to expansion phase. Value-enhancing healthcare.
From early sales to expansion phase. Preventive health and medical services.
Current investment opportunities
Receive information about current investment opportunities
Sign in or create an account to receive information about current share issues.
Selection of executed investments
Capitainer supplies intelligent solutions for self-sampling of blood and plasma. The product qDBS is based on DBS (Dried Blood Spot) technology and is designed for easy home sampling of blood with high precision.
Synartro is developing a unique treatment for knee osteoarthritis by combining two proven drugs, which will offer an effective and safe alternative to today’s treatments.
PharmNovo develops drugs for chronic pain based on a new type of selective delta opioids. The main candidate PN6047 shows promising results on effective pain relief without negative side effects.
Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.